Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Butineuron
- Development stage
- Unknown
- Lead developer
- Laboratorios Lafedar
- Modality
- Small Molecules
- Administration
- Oral, Parenteral
01
Overview
**Butineuron** is a marketed Lafedar fixed-dose neuropsychiatric product containing gamma-aminobutyric acid and a vitamin B6 form. Its oral tablet and syrup formulations contain gamma-aminobutyric acid plus pyridoxine hydrochloride, while the injectable formulation contains gamma-aminobutyric acid plus pyridoxal phosphate. Lafedar describes it as a normalizer of cerebral metabolism and cerebrotonic; reported uses include cognitive impairment, personality and behavioral disorders, recovery after brain injury, and use as an adjunct to psychotropic treatment. ([lafedar.com](https://lafedar.com/en/producto/butineuron/))
- Brand names
- Butineuron
Beyond the preview
Go deeper on Butineuron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Butineuron.